Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hectorol in Pediatric Patients With CKD Stages 3 and 4 With Secondary Hyperparathyroidism
NCT02859896Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Jan 2017
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of doxercalciferol in secondary hyperparathyroidism (SHPT), sponsored by Sanofi. Started Jan 2017; status: terminated.
02
Drugs
doxercalciferol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT02859896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859896.